Tuesday, 23 Apr 2019

You are here

Zolendronate Protects Against Fracture in Osteopenia

The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.

While it is known that bisphonates have beneficial effects in osteoporosis, their impact in osteopenia has not been shown. 

A 6-year, double-blind trial involving 2000 elderly women (>65 yrs)  with osteopenia (T score −1.0 to −2.5)in the hip or femoral neck were randomized to receive four infusions of zoledronate (5 mg) or saline (placebo group) at 18-month intervals. The primary end point was the time to first occurrence of a nonvertebral or vertebral fragility fracture.

The baseline age was 71±5 years, T score was −1.6±0.5, and the 10-year risk of hip fracture was 2.3%.

A fragility fracture occurred in 190 women in the placebo group and in 122 women in the zoledronate group (hazard ratio with zoledronate, 0.63; 95% confidence interval, 0.50 to 0.79; P<0.001).

The NNT to prevent a fracture in 1 woman was 15.

Women treated with zoledronate had a lower risk of nonvertebral fragility fractures (hazard ratio, 0.66), symptomatic fractures (HR 0.73), vertebral fractures (OR 0.45) and height loss (P<0.001).

The bisphosphonate, zoledronate (zoledronic acid) is marketed by Novartis under the of Reclast.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Intraarticular Trans-Capsaicin Effective in Knee OA

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

Smoking Not Protective Against Knee OA

Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark. An inverse association between OA and smoking had been suggested by several previous studies and a recent meta-analysis.  

FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis

The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

Guidelines for Osteoporosis Management in Postmenopausal Women

New guidelines on the  "Pharmacologic Management of Osteoporosis in Postmenopausal Women," were presented March 25 at ENDO 2019 - The Endocrine Society Annual Meeting and simultaneously published online in the Journal of Clinical Endocrinology & Metabolism. 

Risky Painkillers Commonly Prescribed for Osteoarthritis

Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling. Nevertheless, physicians in a large health system were prescribing those drugs for the condition nearly a third of the time, often in the vulnerable elderly, according to a study reported here.